Filing
1st Quarter - Report
Reporting period
1st Quarter 2025
Jan 1 - Mar 31 · Posted Apr 21, 2025
Money reported
None
Registrations and no-activity reports carry no figure.
Client based in
New Jersey
Lobbyists on this filing
7
-
KEVIN CASEYPreviously held: Senior Pol Dir, Dem Caucus; Counselor, Leg. Dir, Leg. Asst, Rep. Joseph Crowley; Staff Asst, Leg. Correspondent, Rep. Bob Weygand
-
MARTIN DELGADOPreviously held: Staff Dir, House Ag Approps, MilCon/VA Approps; Prof Staff, House Ag Approps, Senate Interior Approps; Budget Analysis, USDA APHIS
-
MICHAELEEN EARLE CROWELLPreviously held: Leg Director, Rep. Denise Majette; Leg Director, Rep. John Lewis; Chief of Staff, US Sen. Bernie Sanders
-
MARTIN REISERPreviously held: Policy Director, Republican Whip Steve Scalise, professional staff House Ways and Means Committee, Chief of Staff, Rep. Dan Miller, Budget Associate, House Budget Committee
-
OLIVIA KURTZPreviously held: Chief of Staff, Leg Director, Dep Leg Director, Sr Leg Asst, US Sen Susan Collins; Dep Staff Dir, Sen Special Comm on Aging; Leg Director, Sr Leg Asst, Leg Asst, Exec Asst, Rep Mike Castle
-
CHANDA BETOURNEY New on this filingPreviously held: Dep. Staff Director and Chief Counsel, Senate Appropriations Cmt; Chief Counsel Civil Law and Oversight, Sen. Counsel, Sen. Judiciary Cmt; Leg Asst. and Projects Dir., Leg. Corresp., Senator Leahy
-
KRISTI REMINGTON New on this filingPreviously held: Deputy Assistant Attorney General, US Department of Justice; Senior Counsel, House Government Reform Committee
Government bodies contacted
2
Lobbying activity
1
Issues and legislative proposals on biosimilars and generics medicines, including but not limited to generics and biosimilar sustainability, pharmaceutical supply chain security, drug shortages, interchangeability, and PBM reform.